Kirkland Advises Bristol-Myers Squibb on $74 B Celgene Buy (1)

Large teams from Kirkland & Ellis and Wachtell Lipton Rosen & Katz played leading roles in Bristol-Myers Squibb’s $74 billion acquisition of Celgene Corp. announced Thursday.

The deal is uniting the two drugmakers, which are both engaged in a competitive market for new cancer treatments.

Kirkland represented BMS in the massive deal, which could amount to the largest merger in the pharma industry ever if approved by shareholders and regulators.

Kirkland’s team on the deal was led by corporate practice partners Daniel Wolf, Jonathan Davis, Ryan Brissette, and David Fox, according to a statement from the firm. That group was ...